Abstract

Background: HIV infection persists for a longer time in AIDS patient compared to many other viral diseases. This is mainly because the HIV resides maximally in lymphatic system mainly the lymph nodes. Most of the present anti-HIV drugs have very poor bioavailability at lymphatic tissue. Hence, pharmaceutical scientists have made many efforts to formulate anti-HIV drugs for targeting lymphatic system. The exploration of nanoparticulate drug delivery systems have been popularly investigated for lymphatic targeting and for improving therapeutic efficacy. Methods: An electronic search was undertaken to review the recent publications and patents from the available resources on nanoformulations of anti-HIV drugs for lymphatic delivery. Results: Various carrier systems such as liposomes, polymeric nanoparticles, solid-lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, dendrimers, and nanocrystals have been tried for lymphatic targeting. These nanoparticles are widely studied as passive targeting carriers for lymphatic systems. There is dearth of active targeting for anti-HIV drugs. The studies on surface modified nanoparticles have shown promising results for lymphatic targeting. Conclusion: One of the reasons for low success rate in targeting the lymphatic tissue is poor-understanding of pharmacokinetic interactions of novel delivery systems in disease pathology. Apart from this, there are several hurdles in biological screening models and clinical trials. These issues should never be neglected in developing newer targeted delivery systems for treatment of AIDS.

Original languageEnglish
Pages (from-to)116-127
Number of pages12
JournalRecent Patents on Nanotechnology
Volume10
Issue number2
Publication statusPublished - 01-08-2016

Fingerprint

Anti-HIV Agents
human immunodeficiency virus
delivery
drugs
lymphatic system
Nanoparticles
nanoparticles
acquired immunodeficiency syndrome
Lipids
Tissue
Dendrimers
Pharmacokinetics
viral diseases
lipids
Liposomes
Micelles
Pathology
Drug products
Nanocrystals
bioavailability

All Science Journal Classification (ASJC) codes

  • Materials Science(all)
  • Condensed Matter Physics
  • Engineering(all)

Cite this

@article{4bcef7f22c41468d89b8a14a3f5270ff,
title = "Lymphatic delivery of anti-HIV drug nanoparticles",
abstract = "Background: HIV infection persists for a longer time in AIDS patient compared to many other viral diseases. This is mainly because the HIV resides maximally in lymphatic system mainly the lymph nodes. Most of the present anti-HIV drugs have very poor bioavailability at lymphatic tissue. Hence, pharmaceutical scientists have made many efforts to formulate anti-HIV drugs for targeting lymphatic system. The exploration of nanoparticulate drug delivery systems have been popularly investigated for lymphatic targeting and for improving therapeutic efficacy. Methods: An electronic search was undertaken to review the recent publications and patents from the available resources on nanoformulations of anti-HIV drugs for lymphatic delivery. Results: Various carrier systems such as liposomes, polymeric nanoparticles, solid-lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, dendrimers, and nanocrystals have been tried for lymphatic targeting. These nanoparticles are widely studied as passive targeting carriers for lymphatic systems. There is dearth of active targeting for anti-HIV drugs. The studies on surface modified nanoparticles have shown promising results for lymphatic targeting. Conclusion: One of the reasons for low success rate in targeting the lymphatic tissue is poor-understanding of pharmacokinetic interactions of novel delivery systems in disease pathology. Apart from this, there are several hurdles in biological screening models and clinical trials. These issues should never be neglected in developing newer targeted delivery systems for treatment of AIDS.",
author = "Yogendra Nayak and Kiran Avadhani and Srinivas Mutalik and Nayak, {Usha Y.}",
note = "cited By 1",
year = "2016",
month = "8",
day = "1",
language = "English",
volume = "10",
pages = "116--127",
journal = "Recent Patents on Nanotechnology",
issn = "1872-2105",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

Lymphatic delivery of anti-HIV drug nanoparticles. / Nayak, Yogendra; Avadhani, Kiran; Mutalik, Srinivas; Nayak, Usha Y.

In: Recent Patents on Nanotechnology, Vol. 10, No. 2, 01.08.2016, p. 116-127.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lymphatic delivery of anti-HIV drug nanoparticles

AU - Nayak, Yogendra

AU - Avadhani, Kiran

AU - Mutalik, Srinivas

AU - Nayak, Usha Y.

N1 - cited By 1

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background: HIV infection persists for a longer time in AIDS patient compared to many other viral diseases. This is mainly because the HIV resides maximally in lymphatic system mainly the lymph nodes. Most of the present anti-HIV drugs have very poor bioavailability at lymphatic tissue. Hence, pharmaceutical scientists have made many efforts to formulate anti-HIV drugs for targeting lymphatic system. The exploration of nanoparticulate drug delivery systems have been popularly investigated for lymphatic targeting and for improving therapeutic efficacy. Methods: An electronic search was undertaken to review the recent publications and patents from the available resources on nanoformulations of anti-HIV drugs for lymphatic delivery. Results: Various carrier systems such as liposomes, polymeric nanoparticles, solid-lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, dendrimers, and nanocrystals have been tried for lymphatic targeting. These nanoparticles are widely studied as passive targeting carriers for lymphatic systems. There is dearth of active targeting for anti-HIV drugs. The studies on surface modified nanoparticles have shown promising results for lymphatic targeting. Conclusion: One of the reasons for low success rate in targeting the lymphatic tissue is poor-understanding of pharmacokinetic interactions of novel delivery systems in disease pathology. Apart from this, there are several hurdles in biological screening models and clinical trials. These issues should never be neglected in developing newer targeted delivery systems for treatment of AIDS.

AB - Background: HIV infection persists for a longer time in AIDS patient compared to many other viral diseases. This is mainly because the HIV resides maximally in lymphatic system mainly the lymph nodes. Most of the present anti-HIV drugs have very poor bioavailability at lymphatic tissue. Hence, pharmaceutical scientists have made many efforts to formulate anti-HIV drugs for targeting lymphatic system. The exploration of nanoparticulate drug delivery systems have been popularly investigated for lymphatic targeting and for improving therapeutic efficacy. Methods: An electronic search was undertaken to review the recent publications and patents from the available resources on nanoformulations of anti-HIV drugs for lymphatic delivery. Results: Various carrier systems such as liposomes, polymeric nanoparticles, solid-lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, dendrimers, and nanocrystals have been tried for lymphatic targeting. These nanoparticles are widely studied as passive targeting carriers for lymphatic systems. There is dearth of active targeting for anti-HIV drugs. The studies on surface modified nanoparticles have shown promising results for lymphatic targeting. Conclusion: One of the reasons for low success rate in targeting the lymphatic tissue is poor-understanding of pharmacokinetic interactions of novel delivery systems in disease pathology. Apart from this, there are several hurdles in biological screening models and clinical trials. These issues should never be neglected in developing newer targeted delivery systems for treatment of AIDS.

UR - http://www.scopus.com/inward/record.url?scp=84978299737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978299737&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84978299737

VL - 10

SP - 116

EP - 127

JO - Recent Patents on Nanotechnology

JF - Recent Patents on Nanotechnology

SN - 1872-2105

IS - 2

ER -